Last reviewed · How we verify

NCT06872710: NBHAP

Prognostic Value of Vitamin D and Intact Parathyroid Hormone (iPTH) in Pulmonary Hypertension

Not yet recruiting Last updated 12 March 2025
What this trial tests

trial in Pulmonary Hypertension in 345 participants. Not yet recruiting.

Timeline
1 March 2025
Primary endpoint
1 July 2025
28 December 2025

Quick facts

Lead sponsorUniversidad Complutense de Madrid
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment345
Start date1 March 2025
Primary completion1 July 2025
Estimated completion28 December 2025

Conditions studied

Sponsor

Universidad Complutense de Madrid — full company profile →

Who can join

Eligibility, any sex, with Pulmonary Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this observational study is to analyse the prognostic value of 25(OH)-vitamin D, iPTH and other serum biomarkers in patients with pulmonary hypertension. Serum samples are obtained from the Spanish Biobank of pulmonary hypertension. Clinical data will be collected from the Spanish registries on pulmonary hypertension (REHAP and REHAR).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pulmonary Hypertension

Currently open trials in the same condition.

Other Universidad Complutense de Madrid trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06872710.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing